- Home
- CHRS vs FLC Comparison
CHRS vs FLC Comparison
Compare CHRS & FLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CHRS | FLC |
|---|---|---|
| Founded | 2010 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 177.7M | 172.4M |
| IPO Year | 2014 | 2003 |
Fundamental Metrics
Financial Performance| Metric | CHRS | FLC |
|---|---|---|
| Price | $1.33 | $16.24 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $5.51 | N/A |
| AVG Volume (30 Days) | ★ 1.1M | 18.6K |
| Earning Date | 05-07-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 472.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $73.08 | N/A |
| Revenue Next Year | $30.94 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.09 | $15.89 |
| 52 Week High | $2.62 | $18.09 |
Technical Indicators
Market Signals| Indicator | CHRS | FLC |
|---|---|---|
| Relative Strength Index (RSI) | 48.00 | 25.15 |
| Support Level | $1.33 | $15.89 |
| Resistance Level | $1.51 | $17.00 |
| Average True Range (ATR) | 0.08 | 0.10 |
| MACD | 0.00 | -0.03 |
| Stochastic Oscillator | 25.00 | 0.00 |
Price Performance
Historical ComparisonAbout CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.
About FLC Flaherty & Crumrine Total Return Fund Inc
Flaherty & Crumrine Total Return Fund Inc is a diversified, closed-end investment management company. Its investment objective is to provide its common shareholders with a high current income. The fund's secondary investment objective is capital appreciation.